Seminars in Oncology
Volume 32, Issue 1 , Pages 35-42, February 2005

Chemotherapy for advanced colorectal cancer: Let’s not forget how we got here (until we really can)

  • Bert H. O’Neil

      Affiliations

    • University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
    • Corresponding Author InformationAddress reprint requests to Bert H. O’Neil, MD, Assistant Professor of Medicine, UNC Lineberger Comprehensive Cancer Center, 3009 Old Clinic Building, CB #7305, Chapel Hill, NC 27599-7305.
  • ,
  • Richard M. Goldberg

      Affiliations

    • University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.

Physicians and patients alike have been heartened by the recent advances in the treatment of colorectal cancer. The emergence of novel agents that are active in the treatment of this devastating disease, such as cetuximab and bevacizumab, has been particularly notable. However, even before these recent events, a substantial change in prognosis for patients with metastatic colorectal cancer had occurred as a result of advances in traditional chemotherapeutic agents. Refinements in dose, schedule, and sequence continue to be made that could lead to further improvements in outcomes. Additionally, new chemotherapeutic agents with promise for activity in colorectal cancer are being studied. Chemotherapy is likely to remain a central element of the treatment strategy. Our understanding of its current role is discussed in this article.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(04)00459-2

doi:10.1053/j.seminoncol.2004.09.030

Seminars in Oncology
Volume 32, Issue 1 , Pages 35-42, February 2005